Oppenheimer Highlights Amgen's (AMGN) Strong Revenue Growth and Breakthrough in Cardiovascular Study

By Yahoo! Finance   |   1 month ago
Oppenheimer Highlights Amgen's (AMGN) Strong Revenue Growth and Breakthrough in Cardiovascular Study

Amgen Inc. is a California-based biopharmaceutical company with a solid performance. It recently achieved positive trial results for its drug Repatha in reducing cardiovascular events. The company is also making efforts to lower drug costs and has a reliable dividend growth history.

Read More

Did you find this insightful?